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The incidence, outcome and predictors of the in-hospital
development of cardiogenic shock and its prognostic signif-
icance were analyzed in 845 patients presenting with acute
myocardial infarction . Cardiogenic shock developed after
hospitalization in 60 patients (7.1%). In half of these
patients, cardiogenic shock developed at least 24 h after
hospital admission . The in-hospital mortality rate was > 15
times higher for patients with cardiogenic shock than for
patients without shock (65 .0% versus 4.3%, respectively, p
< 0.001) . Enzymatic evidence of infarct extension occurred
in 23 .3% of the patients with shock compared with 7 .4% of
those without shock (p < 0 .0001) .
Multivariate analysis indicated that independent predic-
tors for the in-hospital development of cardiogenic shock
Cardiogenic shock is now the most frequent cause of in-
hospital death among patients with acute myocardial infarc-
tion, with a mortality rate in some series (1-4) exceeding
80%. Better survival rates have been reported among pa-
tients with cardiogenic shock after coronary artery bypass
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were age >65 years (p = 0 .007), left ventricular ejection
fraction on hospital admission <35% (p = 0 .007), large
infarct as estimated from serial enzyme determinations
(that is, peak creatine kinase-MB isoenzyme >160 IU/liter
(p = 0.008), history of diabetes mellitus (p = 0 .011) and
previous myocardial infarction (p = 0 .012) . Patients with
three, four or five of these risk factors had a 17 . %, 33.7%
or 54 .4% probability, respectively, of developing cardio-
genic shock after hospital admission . Left ventricular func-
tion, as reflected by left ventricular ejection fraction (p =
0.04) and severity of left ventricular wall motion abnormal-
ity (p = 0 .04), was the most important determinant of
in-hospital mortality in the patients with cardiogenic shock .
(J Am Coll Cardiol 1 8  ;14 40-6)
surgery, particularly those in whom the infarct is associated
with a hemodynamically significant but correctable mechan-
ical lesion (5- ), and in patients after percutaneous trans-
luminal coronary artery angioplasty (10-14) . In many cases,
cardiogenic shock occurs hours or even days after the onset
of infarction (1,15), suggesting that earlier aggressive ther-
apy may be feasible. However, even though limiting infarct
size by means of early reperfusion and thereby preventing
cardiogenic shock remains a primary goal, many patients
present to the medical care system too late to salvage
substantial myocardium ; in others, thrombolytic therapy is
contraindicated or unsuccessful . The early identification of
patients at high risk of developing postinfarction cardiogenic
shock might allow the selection of such patients for early
aggressive therapy in an attempt to reduce the extremely
high mortality rate associated with this condition .
Most prior studies (3,4, ,16-20) of patients with cardio-
genic shock have been more concerned with characteristics
affecting the prognosis than with factors that predict the
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subsequent development of this condition. Others (1,3,4,
 ,16-21) have been limited by not including a control group
of patients without cardiogenic shock . In addition, many
studies (3,4, ,16-1 ,21-23) have not discriminated between
patients in whom cardiogenic shock is already established on
hospital admission and those in whom it develops later .
Thus, the patient most likely to develop cardiogenic shock
after hospitalization has yet to be clearly characterized . The
Multicenter Investigation of Limitation of Infarct Size (MI-
LIS) study (24) excluded patients with established cardio-
genic shock at the time of hospital admission, thus creating
a data base in which it was possible to examine the devel-
opment of cardiogenic shock associated with myocardial
infarction after hospital admission with regard to incidence,
risk factors, role of infarct extension, outcome and prognos-
tic factors .
Methods
Study patients . The MILLS study was designed to inves-
tigate the effects of propranolol or hyaluronidase therapy on
infarct size
. Patients were eligible for enrollment if they were
<76 years of age, had chest pain typical of myocardial
ischemia for ?30 min, presented within 18 h of the onset of
pain and had electrocardiographic (ECG) changes suggestive
of acute ischemia or evolving infarction (24) .
Among the 2, 31 patients who satisfied the MILLS inclu-
sion criteria, 131 (4 .5%) were excluded from entry into the
trial because of the presence of cardiogenic shock at the time
of hospital admission
. Other exclusion criteria, the method
used to obtain informed consent, guidelines for standard
care, details of drug administration and methods of data
collection have been described elsewhere (24) . Of  85 pa-
tients randomized into the study, 84  (86 .2%) developed
plasma enzyme evidence of myocardial infarction; these
form the basis for the present study .
Patients were managed according to a standard protocol
that restricted the use of nitrates, heparin and beta-
adrenergic blocking agents to specific situations . Throm-
bolytic therapy and early postinfarction coronary angio-
plasty were not used in this study, which terminated
enrollment on December 31, 1 83 .
Data collection . After enrollment into the MILLS study,
baseline measurements were obtained that included a 12 lead
ECG and rest radionuclide ventriculogram . Throughout each
patient's hospitalization, details concerning the history and
physical examination, daily clinical events, vital signs, spe-
cial procedures (including Swan-Ganz catheterization) and
results of routine laboratory tests were recorded . The con-
dition of all patients was ascertained at 6 month intervals by
a questionnaire administered by telephone
.
Core laboratories analyzed total plasma creatine kinase
(CK) activity, MB CK isoenzyme activity, ECG localization
of infarction and radionuclide ventriculograms (24) . Plasma
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samples for CK and MB CK analyses were collected at the
clinical units before treatment, then at 1 h intervals for 4 h,
at 2 h intervals for 4 h, at 4 h intervals for 72 h, every 8 h for
the next 2 days and every 12 h thereafter through to day 14 .
Definitions . A patient was considered to have had an
acute myocardial infarction if any of the following criteria
were met  1) MB CK ? 13 IU/liter in two or more sequential
plasma samples obtained within a 12 h period and manifest-
ing a pattern compatible with the serial changes indicative of
myocardial infarction; 2) MB CK >_ 13 IU/liter obtained in
one plasma sample, but representing a threefold increase
above baseline values ; and 3) MB CK ?13 IU/liter obtained
in the only sample .
Development of cardiogenic shock after entry into the
study was defined by the development of. 1) a systolic blood
pressure < 0 mm Hg or mean arterial pressure <70 mm Hg
in the absence of hypovolemia ; 2) a cardiac index <2
.0
liters/min per m2 with a wedge pressure > 18 mm Hg and a
mean arterial pressure <60 mm Hg; or 3) the requirement for
vasopressors to maintain cardiac function above the afore-
mentioned levels of arterial pressure and cardiac index . The
narrative history and hemodynamic data of all patients
recorded as having developed cardiogenic shock were re-
viewed to confirm that they met the criteria just mentioned
and that they were associated with abnormalities of the
peripheral circulation (for example, oliguria, mental status
changes, skin perfusion changes) .
Enzymatic evidence of infarct extension or reinfarction
was defined in either of two ways . First, when the initial
elevation of MB CK had not returned to baseline, infarct
extension or reinfarction was defined as an elevation of MB
CK >3 IU/liter occurring >_48 h after the onset of symptoms,
representing an increase of >25% of the mean of the two
preceding values, having an absolute value of > 13 IU/liter
and persisting in at least two samples over an interval of 8 h,
unless the elevation occurred in the last available sample (in
which case it was still considered to be indicative of infarct
extension). Second, when the initial elevation of MB CK had
returned to the baseline value, infarct extension or reinfarc-
tion was defined as an elevation of MB CK to ?13 IU/liter
and ?50% over the mean of the two preceding samples,
occurring >_48 h after the onset of symptoms and persisting
in at least two samples over a period of 8 h, unless the
elevation occurred in the last available sample (in which case
it still qualified as being indicative of infarct extension)
(25) .
Infarct size index
by MB CK gram equivalents per square
meter of body surface area (MB CK-g-eq/m 2
) was calculated
according to the method published previously
(25) . Peak MB
CK for each patient was defined as the highest value of all
MB CK measurements for that patient
.
Q wave infarction
was defined by the presence of new Q
waves >30 ms in width and ?0
.2 mV or more in depth .
Impulse conduction defect
was defined as a PQ interval of
?0
.20 s or second or third degree atrioventricular (AV)
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block . Intraventricular conduction defect included left bun-
dle branch block, right bundle branch block, left anterior
hemiblock and left posterior hemiblock . Maximal ST seg-
ment displacement was recorded as the greatest ST segment
elevation or depression (in millimeters) in any one lead of the
admission 12 lead ECG .
Ejection fraction was determined from the admission
radionuclide ventriculogram obtained immediately before
enrollment . If this study was not yet available, the radionu-
clide ventriculogram recorded  0 min after enrollment was
used (24) .
The percent of segments with abnormal left ventricular
wall motion was determined from the admission radionuclide
ventriculogram and recorded as the proportion of abnormal
segments to all segments . A program to quantify regional
wall motion was developed for use in the MILLS study and
permitted evaluation of wall motion in multiple views from
the end-systolic and end-diastolic frames (24) .
Statistical analysis . The chi-square test was used to de-
termine whether the proportion of patients with a particular
risk factor in the group with cardiogenic shock was equiva-
lent to that in the group without cardiogenic shock . The t test
was used to determine whether the mean values of a contin-
uous risk factor for these two patient groups were equal .
Multivariate analysis used stepwise logistic regression, with
in-hospital cardiogenic shock as the dependent variable .
Results
Incidence of shock . Of the 84  MILLS study patients with
enzymatic evidence of myocardial infarction, 60 developed
cardiogenic shock after hospital admission hospital, whereas
785 did not. Four patients could not be confidently catego-
rized into either group because of a lack of sufficient hemo-
dynamic data . Thus, the incidence rate of in-hospital devel-
opment of cardiogenic shock after myocardial infarction was
7.1%. There were no differences in the proportion of patients
developing cardiogenic shock among the various MILLS
study treatment groups . Therefore, except for the four
"uncategorized" patients, the following analyses include the
entire cohort of patients with myocardial infarction in the
MILLS study, irrespective of the treatment group .
Time course . The time interval from the onset of symp-
toms to registration in the emergency room was the same
(average 3 .0 h) for the patients who developed cardiogenic
shock and those who did not. The average time from
randomization to onset of cardiogenic shock was 3 .4 ± 0.8
days. Half of the patients developed cardiogenic shock >_24
h after their admission to the hospital (Fig . 1) .
Clinical findings and hemodynamic data (Table 1) . The
patients who developed cardiogenic shock in hospital had
greater clinical and hemodynamic evidence of impairment of
left ventricular function at the time of admission to the
hospital than those who did not develop cardiogenic shock .
The former had a significantly higher heart rate, lower
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Figure 1. Time from randomization into the MILLS study to the
onset of in-hospital cardiogenic shock .
systolic and diastolic blood pressures and a greater incidence
of abnormal neck vein distension, orthopnea and pulmonary
rales . The lowest mean systolic and diastolic blood pressures
on the day of symptom onset and during established cardio-
genie shock were  3 .7 ± 3.4 and 57 .0 ± 3 .7 mm Hg,
respectively, with a maximal heart rate of 102 .6 ± 4.0
beats/min . A proportion of patients had a systolic blood
pressure > 0 mm Hg . However, these patients were classi-
fied as having cardiogenic shock either because this arterial
pressure required support by vasopressor agents or the
cardiac index was <2.0 liters/min per m 2 , with a mean
arterial pressure <60 mm Hg despite adequate left ventric-
ular filling pressures (that is, wedge pressure >18 mm Hg) .
This accounts for the low mean systolic blood pressure for
the cardiogenic shock group being slightly > 0 mm Hg .
Thirty-eight (63 .3%) of the 60 patients with cardiogenic
shock were monitored hemodynamically with the use of a
Swan-Ganz catheter. Among these patients, the lowest mean
cardiac index during established cardiogenic shock was 1 .7
± 0.5 liters/min per m 2 .
Risk factors for cardiogenic shock (Tables 2 and 3).
Univariate analyses identified the following factors present
at the time of hospital admission or early in the hospital
course that were related to the in-hospital development of
cardiogenic shock (Table 2) . These were age, poor left
Table 1. Physical and Hemodynamic Findings on Admission to
the Hospital in 845 Patients
Data are reported as mean values ± standard error
. BP = blood pressure .
Cardiogenic
Shock
(n = 60)
No
Cardiogenic
Shock
(n = 785) p Value
Heart rate (beats/min) 86 .5 ± 2 .6
7  .2 ± 0 .6 0 .001
Systolic BP (mm Hg)
128 .0 ± 4 .2 144 .  ± 1 .1 0 .0001
Diastolic BP (mm Hg) 83 .5 ± 3 .1  0 .2 ± 0 .7
0 .02
Abnormal neck vein
distension (%)
40 .0 13 .2 <0.0001
Pulmonary rales (%)
66 .7 43 .4 <0.0001
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Abbreviations as in Table 2 .
Table 2 .
Patient Characteristics and Univariate Analysis of Potential Risk Factors for Development
of In-Hospital Cardiogenic Shock
ventricular function reflected in left ventricular regional wall
motion abnormality, large infarct size determined by infarct
size index or peak MB CK, history of diabetes mellitus,
previous myocardial infarction, maximal ST segment dis-
placement (positive or negative) on the admission ECG,
prior congestive heart failure, history of angina, acute ante-
rior myocardial infarction and female gender . Notably, after
the stepwise logistic regression analyses, the site of infarc-
tion and magnitude of ST segment displacement on the
admission ECG proved not to be independent risk factors for
the development of cardiogenic shock . There was no asso-
ciation of cardiogenic shock with early peaking of the MB
CK, presence or absence of acute Q wave infarction, history
of hypertension, duration of initial chest pain, recent change
in pattern of angina, time interval from chest pain to treat-
ment or presence of postinfarction ischemic chest pain .
Table 3. Independent Predictors for Cardiogenic Shock by
Multivariate Analysis
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*Excludes patients in whom site of myocardial infarction could not be located   texcludes patients in whom type
of myocardial infarction could not be defined . Data are reported as mean ± standard error . CHF = congestive heart
failure   CK = creatine kinase   ECG = electrocardiogram   LV = left ventricle   LVEF = left ventricular ejection
fraction   MB CK = MB fraction of creatine kinase   MI = myocardial infarction .
With use of a stepwise multivariable selection process,
age >65 years, admission left ventricular ejection fraction
<35%, peak MB CK >160 IU/liter, history of diabetes
mellitus and previous myocardial infarction were found to be
independently predictive for the development of in-hospital
cardiogenic shock (Table 3) . The probability values for
developing cardiogenic shock after hospitalization according
to the number of independent risk factors present in an
individual patient are shown in Figure 2 . This probability is
1 .7%, 3 . %, 8
.6%, 17 . %, 33 .7% or 54.4% for patients with
zero, one, two, three, four or five independent risk factors,
respectively .
Infarct extension or reinfarction (Table 4) . Enzymatic
evidence of infarct extension or reinfarction occurred in
23 .3% of patients who developed cardiogenic shock com-
pared with a 7 .4% incidence rate among patients who did not
develop shock (p < 0 .0001) . In 64 .2% of the patients with
cardiogenic shock and infarct extension or reinfarction, the
latter was clearly documented to have occurred before or at
the time of shock . In the remaining one-third, it was reported
to have occurred after the establishment of shock . For this
reason. infarct extension was not entered into the model for
predictors of cardiogenic shock . The incidence of recurrent
ischemic pain during the hospital admission was similar in
the two groups (50 .0% of the patients with, 43 .8% of patients
without cardiogenic shock, p = 0 .35) .
Characteristic
Cardiogenic
Shock
(n = 60)
No Cardiogenic
Shock
(n = 785) p Value
Age (yr)
61 .4 ± 1 .1 56 .5 ± 0 .4
0 .0003
LVEF (%)
35 .  ± 2 .0 46 .7 ± 0 .6 0 .0001
LV akinetic/dyskinetic (%) 25 .8 ± 2 .8
16 .0 ± 0 .1 0 .0001
Infarct size index (MB CK-g-eq/m2) 26.  ± 3 .1 16 .7 ± 0 .5
0 .0001
Peak MB CK (IU/liter) 187 .2 ± 16 .8
143 .7 ± 16 .8 0 .003
History of diabetes (%) 36 .7 17 .1
<0 .001
Previous Ml (%)
3  .0 22 .2 0 .003
Maximal ST displacement on admission
ECG (mm)
3.5 ± 0 .3 2 .8 ± 0
.1 0 .01
16 .7 7 .6History of CHF (%) 0 .01
History of angina (%)
50 .0 34 .8 0 .02
Anterior Ml* (%) 80 .4 (n = 51) 65 .1 (n = 727)
0 .03
Male (%) 61 .7
73 .6 0 .04
Q wave MIt (%( 65 .  (n = 44) 6  .0 (n = 687) 0 .67
Early peaking MB CK (I5 h) (%) 25 .0 26.2 0 .83
History of hypertension (%) 56 .7
53 .4 0 .62
Duration of chest pain (h) 7 .4 ± 2 .2 6 .3 ± 0 .5
0
.51
Time from chest pain to treatment (h)
3
.0 ± 0 .4
3 .0 ± 0 .1 0 . 7
Change in angina) pattern in 3 weeks
before admission (%)
50 .0 40 .5
0
.15
Variable p Value
Age >65 yr 0 .007
LVEF <35% 0 .007
Peak MB CK >160IU/liter 0.008
Diabetes mellitus 0 .011
Previous MI 0 .012
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0 1 2 3 4 5
No . of Independent Risk Factors Present
Figure 2. Predicted probability for the in-hospital development of
cardiogenic shock according to the number of independent risk
factors present . Risk factors include age >65 years, left ventricular
ejection on admission <35%, peak MB CK > 160 IU/liter, history of
diabetes mellitus and previous myocardial infarction . MB CK = MB
fraction of creatine kinase .
Other in-hospital complications and therapy (Table 4) .
The patients with cardiogenic shock had a significantly
higher incidence of AV and intraventricular conduction
defects, congestive heart failure, cardiac arrest, cardiac
arrhythmia, ventricular septal rupture and significant mitral
regurgitation during hospitalization than did those without
shock. However, the incidence of ventricular septal rupture
and significant mitral regurgitation in patients with shock
was relatively low (5
.1% and 10
.3%, respectively) . A signif-
icantly higher fraction of patients with shock than those
without this complication received procainamide and quini-
Table 4. Complications and Therapy During Hospital Admission
*Significantly difference ; tincludes both ventricular and supraventricular
arrhythmias
; #dopamine, dobutamine, epinephrine or norepinephrine .
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dine
. Seventy-three percent of the patients with cardiogenic
shock received intravenous inotropic support (dopamine,
dobutamine, epinephrine or norepinephrine), whereas 26 .7%
had intraaortic balloon pump support for a mean time of 4 .8
± 0.  days .
Outcome . Thirty-nine (65 .0%) of the 60 patients who
developed cardiogenic shock after hospital admission died
during their hospital stay . This represented 53.4% of all
in-hospital deaths in the MILLS infarct cohort and was 15
times higher than the mortality rate in patients who did not
develop cardiogenic shock (65 .0% versus 4 .3%, respec-
tively, p < 0.001). Of the patients with cardiogenic shock
who died in hospital, 43 .5% had an episode of ischemic chest
pain within 24 h of death and 43 .5% died within 3 days of the
initial myocardial infarction . Follow-up study of all patients
revealed a cumulative 1 year mortality rate of 70.0% and
12.4%, respectively, for the patients with and without car-
diogenic shock, (p < 0 .001) .
Predictors of hospital mortality in patients with cardiogenic
shock. Among the patients who subsequently developed
cardiogenic shock, left ventricular ejection fraction mea-
sured by radionuclide ventriculography at randomization or
 0 min later was 32.  ± 2 .4% in the nonsurvivors compared
with 41 .8 ± 3.5% in the survivors of the hospital stay (p =
0.04). Moreover, the former group had greater left ventric-
ular wall akinesia or dyskinesia than did the survivors (2  . 
± 3
.4% versus 17.7 ± 4
.2%, respectively, p = 0 .04) .
Although the in-hospital mortality was dependent on left
ventricular function, it was unrelated to other factors eval-
uated, which included age, gender, site of infarction, history
of angina, diabetes mellitus, congestive heart failure, previ-
ous myocardial infarction, ST segment displacement on the
admission ECG, acute infarct size or type (that is, Q wave or
non-Q wave myocardial infarction), timing of peak MB CK
release, infarct extension, treatment with hyaluronidase or
propranolol, intraventricular conduction defects or recurrent
in-hospital ischemic pain .
Discussion
Cardiogenic shock developing after hospitalization oc-
curred in 7.1% of a large group of patients presenting with
acute myocardial infarction
. The in-hospital mortality rate
among these individuals was 65% and accounted for slightly
more than half of all in-hospital deaths among the MILLS
infarct cohort . Notably, approximately 50% of the patients
developed cardiogenic shock >24 h and not infrequently
some days, after hospital admission . Nearly 25% of the
patients with cardiogenic shock had enzymatic evidence of
infarct extension or reinfarction-three times the incidence
rate of the patients without cardiogenic shock .
Predictors of cardiogenic shock . Independent predictors
for the in-hospital development of cardiogenic shock were
age >65 years, admission left ventricular ejection fraction
Cardiogenic
Shock
(n = 60)
(%)
No
Cardiogenic
Shock
(n = 785)
(%) p Value
Infarct extension 23 .3 7 .4 <0.0001
Intraventricular conduction
defect
53 .3 16 .  <0.001*
Impulse conduction defect 53 .3 18 .7 <0 .001
Congestive heart failure 81 .7 28 .8 <0.001*
Cardiac arrestt
71 .7 8 .  <0.001*
Arrhythmia
 8 .3 84
.7 0.004*
Ventricular septal rupture 5 .1 0.6 0 .001
Mitral regurgitation 10.3 3 .4 0 .00 *
Recurrent ischemic pain 50 .0
43 .8 0 .35
Digoxin 63 .3 2  .8 <0 .0001*
Procainamide
27 .0 16 .4 <0 .0001*
Quinidine 23 .0 13 .5 0 .04*
Propranolol 18 .3 2  .4 0 .07
Lidocaine
86 .7 77 .4 0 .1
Disopyramide 1 .7 0 .1 0 .55
Intravenous inotropes$
73 .3 7 .0 <0 .001
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<35%, peak MB CK >160 IU/liter, history of diabetes
mellitus and previous myocardial infarction . The presence of
three or more of these factors predicts a substantial risk for
the subsequent development of cardiogenic shock, that is, a
17. % (three risk factors) to 54 .4% (five risk factors) proba-
bility . Left ventricular function on admission was the most
important single prognostic factor for in-hospital mortality
among patients who later developed cardiogenic shock .
Most prior studies have lacked a control group for com-
parison of predictive factors for the development of cardio-
genic shock (1,3,4, ,16-18,20,21) or have been more con-
cerned with risk factors for mortality than with those
predictive of the subsequent development of cardiogenic
shock (3,4, ,16-20) . In addition, previous studies have not
discriminated between those patients with cardiogenic shock
on admission to the hospital and those who develop it after
admission (3,4, ,16-1 ,21-23) and have relied on either
necropsy or enzymatic data in selected cases to evaluate the
part played by infarct extension or reinfarction (22,23,26,27) .
The MILLS study is uniquely suited to examine the in-
hospital development of postmyocardial infarction cardio-
genic shock because it excluded those patients who had
cardiogenic shock at the time of hospital admission (25) . Its
large, well characterized study group allows for a compara-
tive study of predictive and prognostic factors for cardio-
genic shock. Moreover, the near complete follow-up pro-
vides a strong basis for evaluating outcome and prognostic
factors . Because the study was terminated in 1 83, this
group of patients was not treated with thrombolytic therapy
or coronary angioplasty . These therapies may have influ-
enced the incidence of cardiogenic shock in current practice,
but are unlikely to have altered the predictors of cardiogenic
shock. Finally, the extensive MB CK sampling undertaken
enables the assessment of the roles of infarct extension or
reinfarction and of early peaking in the development of
cardiogenic shock .
Time course of cardiogenic shock development . The delay
in onset of cardiogenic shock after hospital admission found
in many of our patients may have reflected additional myo-
cardial ischemia or necrosis after the initial infarction, re-
sulting in cumulative left ventricular dysfunction sufficient to
produce cardiogenic shock . Gutovitz et al . (27) demon-
strated enzymatic evidence of progressive myocardial necro-
sis in selected cases of cardiogenic shock, and necropsy
studies (22,23,26) have confirmed the presence of infarct
extension or reinfarction in many patients with cardiogenic
shock. Identification of infarct extension in approximately
25% of our patients with cardiogenic shock is probably an
underestimation because it does not include those patients
whose infarct extension occurred within the first 48 h of the
initial infarction . These patients were excluded because
enzymatic evidence of infarct extension or reinfarction in the
MILLS study was defined as a secondary increase in MB CK
HANDS ET AL .
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after 48 h from the onset of chest pain to allow a clear
separation between primary and secondary events .
In most cases, infarct extension or reinfarction was
documented to have occurred before or at the time of
cardiogenic shock, and may have contributed to the estab-
lishment of shock in these patients . The precipitating factor
in the remaining patients with delayed onset of shock is not
clear. Ongoing myocardial ischemia without necrosis may
have contributed . Half the patients had recurrent episodes of
myocardial ischemia during their hospital stay . On the other
hand, ventricular septal rupture and significant mitral regur-
gitation occurred infrequently (that is, in 5 .1% and 10 .3%,
respectively) . Cumulative damage to the left ventricle seems
to be the most important factor in the development of
in-hospital cardiogenic shock because previous myocardial
infarction, acute infarct size and admission left ventricular
ejection fraction were all independent predictors for cardio-
genic shock . In addition, infarct extension, observed in a
significant proportion of cases, undoubtedly contributed to
further left ventricular damage and dysfunction .
Like others (1,28), we found increasing age and diabetes
mellitus to be independently associated with cardiogenic
shock . Anterior infarction was revealed by univariate anal-
ysis to be a predictor for the development of in-hospital
cardiogenic shock. However, when the size of infarction and
severity of left ventricular dysfunction were taken into
account, infarct location was not an independent predictor
for the development of in-hospital shock . Previous studies
(2 -32) have shown that anterior location is generally asso-
ciated with a larger infarction . Moreover, patients with
anterior infarction have greater left ventricular impairment
than do those with inferior infarction of equivalent enzy-
matic size (33) .
Left ventricular dysfunction is the most powerful predic-
tor of prognosis after myocardial infarction (34-37), and we
found the left ventricular ejection fraction and the extent of
left ventricular wall motion abnormality on admission to be
significant predictors of in-hospital mortality in patients with
cardiogenic shock . Although anterior infarction has previ-
ously been associated with earlier death (38), it was not an
independent predictor of hospital mortality among our pa-
tients with shock .
Clinical implications . The identification of risk factors for
the development of in-hospital cardiogenic shock and the
frequent finding of a delay between the time of acute
infarction and the onset of cardiogenic shock have important
clinical implications . Earlier recognition of the patient at
high risk of developing cardiogenic shock may allow initia-
tion of early aggressive therapy in the hope of preventing this
condition and thereby reducing its associated high mortality .
The delay before the onset of cardiogenic shock possibly
reflects the role played by infarct extension in its develop-
ment. Importantly, this delay provides a time window for the
implementation of specific interventions that might prevent
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further myocardial damage . Because the development and
prognosis of cardiogenic shock correlate with total left
ventricular damage (21), such limitation of myocardial dam-
age would be expected to reduce the incidence and mortality
of cardiogenic shock . Therefore, consideration by the clini-
cian should be given for early cardiac catheterization and
possible revascularization in some patients with acute myo-
cardial infarction who have three or more of the independent
risk factors for the development of in-hospital cardiogenic
shock identified in this study .
We are grateful to Kathleen Carney for assistance in the preparation of the
manuscript .
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